How Far Are ADCs from Treating Prostate Cancer?
Antibody-drug conjugates (ADCs) have emerged as a significant platform for precision oncology, demonstrating remarkable efficacy in various solid tumors in recent years. With ongoing innovations in target selection and linker technology, the development of ADCs for the treatment of metastatic castration-resistant prostate cancer (mCRPC) has also made significant strides. This article systematically reviews the latest … Read more